Search

Your search keyword '"Armengol, Carolina"' showing total 164 results

Search Constraints

Start Over You searched for: Author "Armengol, Carolina" Remove constraint Author: "Armengol, Carolina"
164 results on '"Armengol, Carolina"'

Search Results

1. Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma

2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

3. Macrophage CD5L is a target for cancer immunotherapy

4. MacroH2As regulate enhancer-promoter contacts affecting enhancer activity and sensitivity to inflammatory cytokines

6. FRI-466-YI Implications and therapeutic potential of neddylation for pediatric liver cancer: hepatoblastoma

8. Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications

14. Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response

15. Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification

16. Investigation of novel hepatoblastoma chemosensitizers based on the inhibition of ABC pumps-mediated drug efflux

17. Characterisation of Aberrant Metabolic Pathways in Hepatoblastoma Using Liquid Chromatography and Tandem Mass Spectrometry (LC-MS/MS).

18. Supplementary Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

19. Data from Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

20. Supplementary Table 3 from Tbx3 Is a Downstream Target of the Wnt/β-Catenin Pathway and a Critical Mediator of β-Catenin Survival Functions in Liver Cancer

21. Supplementary Figure Legends 1-4 from Tbx3 Is a Downstream Target of the Wnt/β-Catenin Pathway and a Critical Mediator of β-Catenin Survival Functions in Liver Cancer

22. Supplementary Figures 1-4 from Tbx3 Is a Downstream Target of the Wnt/β-Catenin Pathway and a Critical Mediator of β-Catenin Survival Functions in Liver Cancer

23. Supplementary Table 2 from Tbx3 Is a Downstream Target of the Wnt/β-Catenin Pathway and a Critical Mediator of β-Catenin Survival Functions in Liver Cancer

24. Identification ofIGF2as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma

26. Abstract PO009: Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma

27. Abstract PO010: Molecular characterization of pediatric hepatocellular carcinoma: genomic, methylomic and transcriptomic analysis

28. Abstract PO011: Proteomic profiling of childhood liver cancer: identification of novel diagnostic and prognostic biomarkers

29. Targeting the Unwindosome by Mebendazole Is a Vulnerability of Chemoresistant Hepatoblastoma

31. Development of Hepatoblastoma organoids as a patient-derived ex-vivo system

32. Abstract 4005: Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma

33. Unravelling the transcriptome of the human tuberculosis lesion and its clinical implications

34. LIM Homeobox-2 Suppresses Hallmarks of Adult and Pediatric Liver Cancers by Inactivating MAPK/ERK and Wnt/Beta-Catenin Pathways

35. Identification of the most vulnerable populations in the psychosocial sphere: a cross-sectional study conducted in Catalonia during the strict lockdown imposed against the COVID-19 pandemic

36. Identification of important regulatory elements using multi-level matrix factorization approaches

37. Data-driven model for molecular targets and drug repositioning

39. Hepatic Stem-like Phenotype and Interplay of Wnt/β-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer

40. Psychosocial impact of the Covid-19 pandemic: Identification of most vulnerable populations

42. SAT-247 - Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification

44. Dual inhibition of DNA methyltransferase 1 and the histone methyltransferase G9a as a new therapeutic strategy in hepatoblastoma

45. LIM Homeobox-2 Suppresses Hallmarks of Adult and Pediatric Liver Cancers by Inactivating MAPK/ERK and Wnt/Beta-Catenin Pathways.

47. FRI271 - Development of Hepatoblastoma organoids as a patient-derived ex-vivo system

49. Abstract 3107: A scientific task force to generate proof-of-concept data packages for clinical trials in pediatric cancers: The hepatoblastoma example

Catalog

Books, media, physical & digital resources